Hutch News

Hutch News

Stories tagged 'Immunology Program'

Good News at Fred Hutch

Celebrating faculty and staff achievements

Nov. 30, 2017

The Parker Institute for Cancer Immunotherapy announced that Dr. Phil Greenberg, head of the Program in Immunology at the Hutch, has joined its team of more than 300 scientists from the academic, nonprofit, biotech and pharma sectors.

View story >


Promising results in trial of engineered T cells in high-risk leukemia

High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia

July 17, 2017 | By Susan Keown / Fred Hutch News Service

Most patients with recurrent chronic lymphocytic leukemia who were enrolled in a small, early- phase trial saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells. Dr. Cameron Turtle, one of the study’s leaders, presented the results on Saturday at the 2016 annual meeting of the American Society of Hematology in San Diego.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Aug. 11, 2016

Dr. Amit Sharma receives Pathway to Independence Award; Dr. Phil Greenberg publishes T-cell findings; Dr. Yanghee Woo chosen for early-career hematology training program

View story >


New clues to treating deadly skin cancer

Small clinical trial finds two forms of immunotherapy may be better than one for treating metastatic melanoma

June 6, 2016 | By Rachel Tompa / Fred Hutch News Service

Matthew Flood, a retired EMT from the Tacoma Fire Department, is one of 10 patients with metastatic melanoma treated with an experimental combination of immunotherapies between 2011 and 2013. In a study published today in the Journal of Clinical Oncology, the research team described the small clinical trial and how the patients have fared in the years following their treatment. Flood is now in complete remission five years after receiving the combo immunotherapy.

View story >


Tailoring immune cells to target leukemia

Promising early trial results show engineered immune cells may help buffer against cancer relapse after bone marrow transplantation

April 21, 2016 | By Sabrina Richards / Fred Hutch News Service

Dr. Phil Greenberg’s team at Fred Hutch has developed methods to genetically modify T cells, a type of immune cell, to specifically seek out cancer cells while they ignore healthy cells. On Wednesday, he presented results of an early-stage trial at the American Association for Cancer Research annual conference in New Orleans that appear to show promise in preventing disease relapse after blood stem cell transplantation.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

April 21, 2016

Women’s Health Initiative receives AACR Team Science Award; Andrew Hsieh awarded AACR NextGen Grant for Transformative Cancer Research; Designing an off-the-shelf nanoparticle-based immunotherapy; Fred Hutch’s Vaccine and Infectious Disease Division contributes to early study of promising Ebola vaccine

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.